SXTP News & Events

60 Degrees Pharmaceuticals announced that it has entered into an exclusive option agreement with the Florida State University Research Foundation covering intellectual property related to the therapeutic development of castanospermine for multiple tick-borne diseases. These fields include Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. "This agreement reflects our belief that castanospermine may have its greatest long-term value as the basis for innovative prescription medicines addressing important unmet needs in tick-borne diseases," said Geoff Dow, CEO of 60 Degrees Pharma.

60 Degrees Pharmaceuticals announced that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study, following a review of safety data from the first six patients from baseline through Day 30.

60 Degrees Pharmaceuticals announced that the company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of Castanospermum australe for non-prescription uses. Castanospermine is the principal component of Australian Chestnut Extract. The FDA has issued a Non-Notification Letter to 60 Degrees Pharma providing feedback on the company's recent filing of a New Dietary Ingredient Notification for Australian Chestnut Extract. 60 Degrees Pharma and the Agency will meet on July 1 to discuss the feedback, including clarification regarding the minimum required "other safety information" to establish the safety of the proposed use of Australian Chestnut Extract in a dietary supplement. Subsequently, the company will submit a revised NDIN.

60 Degrees Pharmaceuticals announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. This patient enrollment puts the Company approximately one month ahead of schedule in recruiting trial participants for the 2026 tick season, suggesting that minimum enrollment in the study could be achieved as soon as early July. Approximately 50 days following enrollment completion, the Company intends to announce the planned date of the interim analyses of study data.